Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria
Photodermatology, Photoimmunology & Photomedicine · 2026-05 · 42 (3)
DOI: 10.1111/phpp.70088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Photodermatology, Photoimmunology & Photomedicine, online erschienen am 10.04.2026. Verfasst von Donna Parkin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Photobiology Unit, Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre…. Hauptthemen laut MEDLINE: Omalizumab, Quality of Life, Urticaria, Solar, Anti-Allergic Agents. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research Manchester Biomedical Research Centre, British Skin Foundation, Manchester Biomedical Research Centre.
Abstract (Originalsprache)
Background
Solar urticaria is a rare photodermatosis in which exquisite photosensitivity can require extreme behavioural adaptations, resulting in a substantial impact on quality of life (QoL). Omalizumab therapy has been demonstrated to improve several clinical outcome measures, but the impact on behavioural measures is poorly understood. Our objectives were to examine daylight exposure behaviours and QoL measures pre‐ and post‐omalizumab therapy.
Methods
Daylight exposure diaries were completed by n = 5 patients with solar urticaria and n = 7 healthy participants during different seasons in England, UK (51.1–53.5 o N). These incorporated a range of measures, including time spent outdoors and clothing worn, and Dermatology Life Quality Index (DLQI) data were also collected.
Results
Prior to omalizumab, patients spent less time outdoors in sunny vs. non‐sunny conditions in spring (mean 10 vs. 29 min/day, p < 0.05) and less than healthy volunteers (44 min in sunny conditions/day). On omalizumab, patients increased their time outdoors in sunny conditions, reaching similar levels to healthy volunteers in spring (45 min/day) and further increasing to 85 min/day in summer. This was accompanied by fewer days with symptoms (symptoms on 75% days in spring pre‐omalizumab vs. 26% days in summer on omalizumab), an apparent doubling of skin surface area exposure and substantial improvement in patients' QoL (mean past‐year DLQI pre‐omalizumab vs. past‐week summer on omalizumab 22 vs. 5, p < 0.001).
Conclusion
Omalizumab therapy was associated with behavioural changes that increase daylight exposure, accompanied by improved QoL. This study highlights the importance of considering a range of outcome measures in assessing response to therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Photobiology Unit, Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Greater Manchester, UK.
- The Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, NIHR Manchester Biomedical Research Centre, The Unive…
ORCID-Profile: Mark D Farrar, Lesley E Rhodes, Kirsty J Rutter
Förderung
- National Institute for Health and Care Research Manchester Biomedical Research Centre
- British Skin Foundation
- Manchester Biomedical Research Centre
Zitieren
APA
Parkin, D., Marjanovic, E. J., Farrar, M. D., Rhodes, L. E., & Rutter, K. J. (2026). Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria. Photodermatology, Photoimmunology & Photomedicine, 42(3). https://doi.org/10.1111/phpp.70088
Vancouver
Parkin D, Marjanovic EJ, Farrar MD, Rhodes LE, Rutter KJ. Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria. Photodermatology, Photoimmunology & Photomedicine. 2026;42(3). doi:10.1111/phpp.70088
BibTeX
@article{Parkin2026,
author = {Parkin, Donna and Marjanovic, Elizabeth J and Farrar, Mark D and Rhodes, Lesley E and Rutter, Kirsty J},
title = {Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria},
journal = {Photodermatology, Photoimmunology & Photomedicine},
year = {2026},
volume = {42},
number = {3},
doi = {10.1111/phpp.70088}
}
EUVIMED